NCT06110793View on ClinicalTrials.gov

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 29, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Lenvatinib

20mg orally PO daily

DRUG

Pembrolizuma

400mg IV Q6W

DRUG

Fulvestrant

500mg IM Q4W

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER